Company intelligence / Profile preview

Rakovina Therapeutics

Vancouver, British Columbia, Canadarakovinatherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Rakovina Therapeutics has presented promising preclinical data for its lead programs targeting PARP1 and ATR using proprietary AI-driven platforms. Their PARP1-selective inhibitors show improved metabolic stability and CNS penetration potential. The ATR inhibitor program is also progressing rapidly, with potent candidates identified for further validation. No clinical trial results are available yet; the company aims to advance one or more candidates into human trials soon.

Therapeutic areas: Oncology
Modalities: Small moleculesAI-discovered drug candidates
Industry: Biotech

Drug pipeline

4 assets

KT-5000

Preclinical

3 more assets in the full pipeline.

Partnerships

Collaboration with Dr. Artem Cherkasov/University of British Columbia for Deep Docking™ platform accessPartnership with Variational AI using their Enki™ platform for novel kinase inhibitor discovery

Beyond the preview

Go deeper on Rakovina Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rakovina Therapeutics.